Last Edition: September 24-25 2020,
Digitally Streamed from Lausanne
The Convergence in Oncology Summit is an international annual assembly of industry leaders, entrepreneurs, and investors active in the field of Oncology to debate and explore synergies that can accelerate the development of the most promising solutions in the field.
From diagnostics to therapeutics, rapid change in technology innovation modifies the landscape faster than any organizations can keep up with. Convergence of technologies from mature and emerging sectors are creating new opportunities that can significantly accelerate disruptive solutions that benefit patients globally.
The principal aim of this Summit is to promote development of new solutions through convergence and sharing of opportunities in the field of Oncology. The Summit is organized by professionals for professionals and we look forward to welcoming you digitally on our platform, for networking and sharing of knowledge among industry leaders, entrepreneurs, academics and investors.
Due to the current worldwide health situation, we will hold the meeting only digitally for the 2020 edition.
Industry Leaders Entrepreneurs Investors
• Panel discussions • Company presentations • Investment outlook
Digitization Prevention Diagnostics Therapeutics
The Summit is organized around eight consecutive plenary panel sessions over two days.
«When talking about Oncology, time is of essence and shortening. The only option we have left today is to converge and work together to speed up oncology research.» Nasri Nahas, CEO Biopôle
Subscribe our contact list to receive updates about the Convergence in Oncology Summit.
Thank you for applying to the next edition of Convergence in Oncology Summit. We will review your application and come back to you in the next days.
Stay updated by following our newsletter
Registrations to the Convergence in Oncology Summit 2020 will open soon!
Corporate attendees: CHF 990.-
Emerging innovators: CHF 750.-
Academia: CHF 750.-
Digital attendees: CHF 490.-
Stay updated by subscribing to our newsletter!